Mefloquine News and Research

RSS

Viewpoints: Fears of health law's adverse selection; GOP's 'fundamental miscalculation;' special deal for Congress keeps dissent low

Yet despite the care the administration took in establishing incentives and safeguards, even some of Obamacare's most committed backers are wondering whether the experiment will work as advertised -; or, like Harvard's P.P.O., go off the rails along the way. Adverse selection is perhaps the direst threat. ... Healthier Americans will probably flock to cheaper bronze plans. And insurers will vie to enroll the healthy. In some states, big insurers have chosen not to participate in exchanges to avoid their strictures. On the outside, they could still sell cheap plans to skim off the healthy and avoid a rule that insurers on the exchanges must also offer more generous silver and gold plans (Eduardo Porter, 8/7).

9 Aug 2013

WHO includes new paediatric therapeutic options to EMLc

This week the World Health Organization released its newly updated 4th WHO Model List of Essential Medicines for Children, in which three treatments developed by the Drugs for Neglected Diseases initiative and its partners have now been included.

12 Jul 2013

Fewer malaria cases, more artesunate resistance on Thai border

Results from an observational study show that the number of reported malaria cases in children and pregnant women on the Thai–Myanmar border has decreased significantly over the past decade.

6 Mar 2013

DNDi in Latin America wins Carlos Slim Health Award for innovations in drug development

Today the Drugs for Neglected Diseases initiative (DNDi) in Latin America received the Carlos Slim Health Award for 10 years of exceptional work and achievements in research and development (R&D) to deliver new treatments for neglected patients in the region. The $100,000 award will be presented at a ceremony in April in Mexico City.

16 Feb 2013

Scientists report on development of new malaria drug

Scientists are reporting development of a new malaria drug that, in laboratory tests, has been twice as effective as the best current medicine against this global scourge and may fight off the disease with one dose, instead of the multiple doses that people often fail to take.

18 Oct 2012

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

Working with individuals with traumatic brain injury (TBI) every day, I see the debilitating effects and long-term struggles firsthand.

9 Oct 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

EMA grants positive scientific opinion for Pyramax to treat malaria

Pyramax-, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day treatment is indicated for acute, uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria in adults and children over 20 kg.

22 Feb 2012

Counterfeit malaria drugs endanger millions of lives

According to researchers fake and poor quality anti-malarial drugs are threatening efforts to control the disease in Africa and could put millions of lives at risk. These counterfeit medicines could harm patients and promote drug resistance among malaria parasites, warns the study, funded by the Wellcome Trust.

18 Jan 2012

Link between changes in malaria parasite and absorption of pharmaceutical compounds

Professor Max Petzold at the Nordic School of Public Health shows in a recent article a link between changes in the malaria parasite and the absorption of pharmaceutical compounds. Increased knowledge of the malaria parasite and the connection with the development of resistance may contribute to the development of new malaria treatments.

26 Sep 2011

Antimalarial drug resistance endangers malarial control measures

Evidence of resistance to the antimalarial drug artemisinin and its derivatives threatens efforts to control malaria in Southeast Asia, and experts fear artemisinin resistance may spread from the Thailand-Cambodia border to affect other malaria endemic countries. Evidence to such effect was presented today at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

20 Nov 2009

Research on malarial drugs for travelers

A new review of existing research finds that a combination drug and the common antibiotic doxycycline allow travelers to fend off malaria with the fewest side effects in areas where the parasite is resistant to a widely accepted preventive treatment.

7 Oct 2009

Emergence of parasites resistant to artemisinin could set back malaria control success

WHO today said that the emergence of parasites resistant to artemisinin at the Thai-Cambodia border could seriously undermine the success of the global malaria control efforts.

25 Feb 2009

Scientists reveal potential new target for anti-malarial drugs

Scientists funded by the Wellcome Trust have identified a key mechanism that enables malaria-infected red blood cells to stick to the walls of blood vessels and avoid being destroyed by the body's immune system. The research, published today in the journal Cell, highlights an important potential new target for anti-malarial drugs.

10 Jul 2008

US military should ensure careful screening prior to prescribing anti-malarial drug, mefloquine

Malaria is a constant threat to US military personnel operating in Afghanistan, but some troops may face further risk, as epidemiologists have revealed a significant prevalence of contraindications to the safe use of the anti-malarial drug, mefloquine.

20 Feb 2008

WHO urges responsible use of antimalarial medicines

In a new report published today, ''Susceptibility of Plasmodium Falciparum to Antimalarial Drugs,'' the World Health Organization (WHO) warns that as more and more people gain access to these life-saving malaria medicines, which combine a drug derived from the plant Artemisia annua with a second, synthetic drug, it is vital that countries closely monitor their effectiveness.

7 Sep 2005

Reliable research about the benefits and harms of treatments for malaria in pregnant women is scarce

Few studies compare the effects of different drug regimes in pregnant women, and many of the best studies were conducted in Southeast Asia, where malaria transmission rates are low, says researcher Lois Orton of the University of York in England.

20 Jul 2005

Sharply increased demand for artemether-lumefantrine, used to treat malaria, is likely to result in a shortage

Sharply increased demand for artemether-lumefantrine, an artemisinin-based combination therapy (ACT) used to treat malaria, is likely to result in a shortage from now until at least March 2005. ACTs are currently the most effective medicines available to treat falciparum malaria -- the deadliest form of the disease.

9 Nov 2004

Mefloquine, an anti-malarial drug plays a critical role in movement, vision and memory

Brown University researchers have discovered that mefloquine, an anti-malarial drug, blocks two gap junction proteins, or connexins, in low doses and with very few side effects in the brains of laboratory mice.

5 Aug 2004